Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases
- PMID: 20672374
- PMCID: PMC2970726
- DOI: 10.1002/humu.21327
Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases
Abstract
The success of prenatal carrier screening as a disease prevention strategy in the Ashkenazi Jewish (AJ) population has driven the expansion of screening panels as disease-causing founder mutations have been identified. However, the carrier frequencies of many of these mutations have not been reported in large AJ cohorts. We determined the carrier frequencies of over 100 mutations for 16 recessive disorders in the New York metropolitan area AJ population. Among the 100% AJ-descended individuals, screening for 16 disorders resulted in ∼1 in 3.3 being a carrier for one disease and ∼1 in 24 for two diseases. The carrier frequencies ranged from 0.066 (1 in 15.2; Gaucher disease) to 0.006 (1 in 168; nemaline myopathy), which averaged ∼15% higher than those for all screenees. Importantly, over 95% of screenees chose to be screened for all possible AJ diseases, including disorders with lower carrier frequencies and/or detectability. Carrier screening also identified rare individuals homozygous for disease-causing mutations who had previously unrecognized clinical manifestations. Additionally, prenatal testing results and experience for all 16 disorders (n = 574) are reported. Together, these data indicate the general acceptance, carrier frequencies, and prenatal testing results for an expanded panel of 16 diseases in the AJ population.
© 2010 Wiley-Liss, Inc.
Figures

Comment in
-
Expanded carrier screening in the Ashkenazi Jewish population.Hum Mutat. 2010 Nov;31(11):v. doi: 10.1002/humu.21381. Hum Mutat. 2010. PMID: 21043044 No abstract available.
Similar articles
-
Comprehensive population screening in the Ashkenazi Jewish population for recurrent disease-causing variants.Clin Genet. 2017 Apr;91(4):599-604. doi: 10.1111/cge.12834. Epub 2016 Aug 22. Clin Genet. 2017. PMID: 27415407 Free PMC article.
-
Premarital and prenatal screening for cystic fibrosis: experience in the Ashkenazi Jewish population.Genet Med. 2004 Sep-Oct;6(5):415-20. doi: 10.1097/01.gim.0000139510.00644.f7. Genet Med. 2004. PMID: 15371906
-
Carrier screening for mucolipidosis type IV in the American Ashkenazi Jewish population.Am J Hum Genet. 2002 Apr;70(4):1023-7. doi: 10.1086/339519. Epub 2002 Feb 13. Am J Hum Genet. 2002. PMID: 11845410 Free PMC article.
-
The Ashkenazi Jewish carrier screening panel: evolution, status quo, and disparities.Prenat Diagn. 2014 Dec;34(12):1161-7. doi: 10.1002/pd.4446. Epub 2014 Jul 31. Prenat Diagn. 2014. PMID: 24996053 Review.
-
Carrier testing for Ashkenazi Jewish disorders in the prenatal setting: navigating the genetic maze.Am J Obstet Gynecol. 2014 Sep;211(3):197-204. doi: 10.1016/j.ajog.2014.02.001. Epub 2014 Feb 5. Am J Obstet Gynecol. 2014. PMID: 24508465 Review.
Cited by
-
Changing trends in carrier screening for genetic disease in the United States.Prenat Diagn. 2015 Oct;35(10):931-5. doi: 10.1002/pd.4647. Epub 2015 Jul 27. Prenat Diagn. 2015. PMID: 26138560 Free PMC article. Review.
-
Health Challenges of the Pacific Region: Insights From History, Geography, Social Determinants, Genetics, and the Microbiome.Front Immunol. 2019 Sep 13;10:2184. doi: 10.3389/fimmu.2019.02184. eCollection 2019. Front Immunol. 2019. PMID: 31572391 Free PMC article. Review.
-
A collaborative genetic carrier screening model for the British Ashkenazi Jewish community.J Community Genet. 2022 Feb;13(1):133-135. doi: 10.1007/s12687-021-00568-7. Epub 2021 Nov 29. J Community Genet. 2022. PMID: 34841494 Free PMC article.
-
Gaucher disease: when molecular testing and clinical presentation disagree -the novel c.1226A>G(p.N370S)--RecNcil allele.J Inherit Metab Dis. 2011 Jun;34(3):789-93. doi: 10.1007/s10545-011-9307-7. Epub 2011 Mar 23. J Inherit Metab Dis. 2011. PMID: 21431620 Free PMC article.
-
MicroRNA screening identifies a link between NOVA1 expression and a low level of IKAP in familial dysautonomia.Dis Model Mech. 2016 Aug 1;9(8):899-909. doi: 10.1242/dmm.025841. Epub 2016 Jun 29. Dis Model Mech. 2016. PMID: 27483351 Free PMC article.
References
-
- Abeliovich D, Quint A, Weinberg N, Verchezon G, Lerer I, Ekstein J, Rubinstein E. Cystic fibrosis heterozygote screening in the Orthodox Community of Ashkenazi Jews: the Dor Yesharim approach and heterozygote frequency. Eur J Hum Genet. 1996;4:338–341. - PubMed
-
- Al Sulaiman A, Suliman A, Al Mishari M, Al Sawadi A, Owaidah TM. Knowledge and attitude toward the hemoglobinopathies premarital screening program in Saudi Arabia: population-based survey. Hemoglobin. 2008;32:531–538. - PubMed
-
- American College of Obstetricians and Gynecologists. ACOG committee opinion. Number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol. 2004;104:425–428. - PubMed
-
- American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol. 2009;114:950–953. - PubMed
-
- Anderson SL, Ekstein J, Donnelly MC, Keefe EM, Toto NR, LeVoci LA, Rubin BY. Nemaline myopathy in the Ashkenazi Jewish population is caused by a deletion in the nebulin gene. Hum Genet. 2004;115:185–190. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical